Defiance Daily Target 2X Long MRNA ETF

KORE

OneMedNet

Ensysce Biosciences

XWELL

Battalion Oil

Applied Optoelectronics

GraniteShares 2x Long DELL Daily ETF

T-REX 2X Inverse CRWV Daily Target ETF

Leverage Shares 2X Long XYZ Daily ETF

MRNA

MRNX

<p>Defiance ETFs has launched a new 2X leveraged ETF linked to Moderna Inc (NASDAQ:MRNA), named the Defiance Daily Target 2X Long MRNA ETF (NYSE:MRNX). This fund aims to provide traders with amplified daily exposure to Moderna's stock, targeting short-term tactical positioning rather than long-term investment. The ETF is designed for sophisticated investors who understand the risks of leveraged products, as it resets daily and is not meant for extended holding periods. This launch reflects the growing trend of single-stock leveraged ETFs in the market.</p>

benzinga_article

Moderna

Betting On Moderna? This New Defiance ETF Turns The Volume Up 2X

<p>Moderna faces challenges as the FDA declines to review its mRNA flu vaccine application, citing concerns over trial comparisons. This decision reflects a shift in regulatory attitudes towards mRNA technology, increasing pressure on Moderna to diversify its product portfolio amid declining COVID-19 vaccine sales. Analysts express concerns about the risks associated with relying on seasonal vaccines in the current environment. Despite setbacks, Moderna's stock has risen 36% over the past year, and the company is seeking further discussions with the FDA regarding its vaccine candidates.</p>

Dow Jones

iShares Global Healthcare

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Moderna's work developing seasonal vaccines is 'risky' under current FDA, analyst says

Defiance Daily Target 2X Long MRNA ETF(MRNX.US)

Betting On Moderna? This New Defiance ETF Turns The Volume Up 2X

Moderna's work developing seasonal vaccines is 'risky' under current FDA, analyst says